Survodutide
Survodutide is a lab-made peptide of 29 amino acids, given as a weekly injection under the skin, that switches on two receptors at once. It has been studied in trials for weight loss, type 2 diabetes and MASH, a liver disease linked to metabolic problems.
At a glance
- Peptide
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- 4.8 mg per Peptide Dosing Protocols. See the source
How much to draw
Full calculator →Opened on 4.8 mg, the figure Peptide Dosing Protocols reports for Survodutide. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Survodutide or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 4.8 mg once weekly · Low: 0.6 mg once weekly · High: 4.8 mg once weekly | once weekly76 weeks · null | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHideSurvodutide is administered at a standard dose of 4.8 mg once weekly. |
- once weekly76 weeks · null
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
Survodutide is administered at a standard dose of 4.8 mg once weekly.
- 1.0 to 2.0 mL per vial
We have not published an audit on Survodutide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Survodutide works on two targets at the same time: one arm lowers appetite and slows how fast food leaves the stomach, and the other appears to raise how many calories the body burns at rest and to lower fat in the liver. Researchers describe it as a dual agonist of the GLP-1 receptor and the glucagon receptor, with glucagon receptors being especially common in the liver, which is the rationale for studying it in MASH. A fatty-acid tail extends how long it lasts in the body, allowing weekly dosing. Long-term heart outcome data are still missing, no head-to-head trial against tirzepatide or retatrutide has been run, and the Phase 3 LIVERAGE liver programme has not reported.
Survodutide acts as a dual GLP-1 and glucagon receptor agonist, targeting both receptors simultaneously. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: stomach and gut effects were most common and were worst while the amount was being increased. In the Phase 2 obesity trial, 75 percent on survodutide had some stomach or gut side effect versus 42 percent on placebo, 25 percent stopped because of side effects versus 4 percent on placebo, and serious side effects occurred in 4.2 percent versus 6.5 percent on placebo. Single notable events were one case of dehydration with kidney failure and one case of angioedema, a serious swelling reaction. In the Phase 2 MASH trial, nausea occurred in 66 percent versus 23 percent on placebo, diarrhoea in 49 percent versus 23 percent, and vomiting in 41 percent versus 4 percent, with 20 percent stopping versus 3 percent. The Phase 3 SYNCHRONIZE-1 topline described stomach and gut effects as mild to moderate and most common during dose increases, with no new safety concerns, and full safety data due in June 2026.
Not ruled out: class warnings for GLP-1 drugs apply, covering pancreas inflammation and, based on animal data, medullary thyroid cancer. A small rise in heart rate was reported, and the risk of low blood sugar is higher alongside insulin or sulfonylureas.
Who should avoid it
People who are pregnant or breastfeeding: survodutide has not been studied in these groups.
People with a personal or family history of medullary thyroid cancer or MEN 2: this is a standard warning for GLP-1 drugs and is applied to survodutide.
People who have had pancreatitis: GLP-1 drugs carry a pancreas inflammation warning, which extends to survodutide.
People with severe stomach or gut disease: nausea, vomiting, diarrhoea and constipation are common with survodutide.
People with diabetes treated with insulin or sulfonylureas: the risk of low blood sugar is higher, so blood sugar may need close medical adjustment.
Children and teenagers: no paediatric data exist.
People with known peptide allergies: one Phase 2 participant had angioedema, a serious swelling reaction.
What gets monitored
Weight, waist size, blood pressure, heart rate, fasting glucose, HbA1c for people with diabetes, and basic liver labs are suggested for monitoring. (reported by Peptide Dosing Protocols)
Common questions
What is survodutide?
It is a 29-amino-acid peptide developed by Boehringer Ingelheim with Zealand Pharma, under the research code BI 456906. It acts on both the GLP-1 receptor and the glucagon receptor at once.
Is survodutide FDA-approved?
No. As of June 2026 it is investigational and not FDA-approved for any human use, and it has no official patient label.
How much weight did people lose with survodutide?
In the Phase 3 SYNCHRONIZE-1 trial of 725 adults over 76 weeks, average weight loss was 16.6 percent versus 3.2 percent on placebo, and 85.1 percent reached at least 5 percent loss. The Phase 2 obesity trial reported dose-related losses from 6.2 percent at the lowest amount to 14.9 percent at the highest, against 2.8 percent on placebo.
What amounts were used in the clinical trials?
The Phase 2 obesity trial used weekly amounts of 0.6 mg, 2.4 mg, 3.6 mg or 4.8 mg over 46 weeks, with the first 20 weeks spent raising the amount. These are trial figures, not an approved regimen.
Can survodutide be bought?
It is not available by prescription in the United States as of June 2026. It remains investigational with no approved use.
How does survodutide compare to retatrutide?
Survodutide acts on two receptors, GLP-1 and glucagon, while retatrutide acts on three, GLP-1, GIP and glucagon. No head-to-head trial between them has been run.
How does survodutide compare to tirzepatide?
Tirzepatide acts on GLP-1 and GIP, while survodutide acts on GLP-1 and glucagon. No head-to-head trial between them has been run.
What are the main survodutide side effects?
Nausea, vomiting, diarrhoea and constipation were the most common in trials. They were worst while the amount was being increased and often improved once it held steady.
Sources
- 01Boehringer Ingelheim. Results from Phase III SYNCHRONIZE-1 obesity trial (press release, April 28, 2026). Boehringer Ingelheim (2026)
- 02Le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology (2024)
- 03Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. New England Journal of Medicine (2024)
- 04Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose-response effects on HbA1c and bodyweight reductions with a dual glucagon/GLP-1 receptor agonist, survodutide, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2024)
- 05Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism (2022)
- 06Authors et al. Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials. PMC (peer-reviewed meta-analysis) (2025)
- 07Mikhail N, Wali S. Survodutide, a promising agent with novel mechanism of action for treatment of obesity and type 2 diabetes. Journal of Endocrinology and Disorders (2024)
- 08ClinicalTrials.gov. A Study to Test How Well Different Doses of BI 456906 Help People With Overweight or Obesity Lose Weight (NCT04667377, Phase 2). ClinicalTrials.gov (2024)
- 09ClinicalTrials.gov. A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Lose Weight (SYNCHRONIZE-1, NCT06066529). ClinicalTrials.gov (2026)
- 10U.S. Food and Drug Administration. Drugs@FDA: search for survodutide approval status (no approved product as of June 2026). FDA.gov (2026)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.